drugset / Trial / NCT02977780

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S

Timeline

Start
2017-02-09
Primary completion
2028-02-01
Completion
2028-04-30

Outcome

Missed primary endpoint

paper None of the experimental therapies demonstrated a significant OS benefit (P > .05). PMID 37722087 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule — Oral
Subject CC-115 Small molecule — Oral
Subject Neratinib Small molecule — Oral
Subject QBS10072S Unknown — —
Background Temozolomide Small molecule — Oral

Indications